IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#98
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$350M
Amir London
Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates in two segments, Proprietary Products and Distribution. The company offers Glassia for use in chronic augmentation and maintenance therapy in adults with emphysema due to AATD. It also provides Bramitob to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = KMDA ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$KMDA KAMADA LTD | 70 | 80 | 93 | 55 | 35.5x | 3.1x | 22.3% | 15.5% | 43.5% | 12.5% | 9.0% | 12.9% | 0.0% | 4.0x | $350M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
KAMADA LTD (KMDA) receives a "Buy" rating with a composite score of 69.8/100. It ranks #98 out of 7,333 stocks in our coverage universe and carries a 4-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Amir London
Chief Executive Officer
Labor Force
360
80
50
74
Audit Verdict: Average governance indicators based on financial metrics.
No recent insider transactions available for KMDA
Headcount
360
HQ Base
REHOVOT,
In-line with peers — no strong momentum signal
Trading at a discount to fundamentals — favorable entry valuation
High profitability & efficiency — strong quality floor supports entry
Low volatility — smoother ride and historically better risk-adjusted returns
Moderate investment profile
Top-rated overall — multiple factors aligned for strong entry
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for KMDA.
View All RatingsConservative accounting — High cash conversion efficiency
Material decline in asset turnover efficiency detected
High margin volatility — erratic forensic earnings quality
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 80 | 91 | -11DRAG |
| MOMENTUM | 55 | 46 | +9ALPHA |
| VALUATION | 93 | 96 | -3NEUTRAL |
| INVESTMENT | 50 | 91 | -41DRAG |
| STABILITY | 74 | 73 | +1NEUTRAL |
| SHORT INT | 81 | 90 | -9DRAG |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy 22.3% (sector -2.5%)
GM 43% vs sector 43%, OM 12% vs sector 1%
Capital turnover N/A, R&D intensity 9.4%
Rev growth 13%, 8yr history
Interest coverage N/A, Net debt/EBITDA -2.0x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
KAMADA LTD receives a Buy rating with a composite score of 69.8/100 and 4 out of 5 stars, ranking #98 of 7,333 stocks in our universe. KMDA displays a favorable combination of factors that positions it above the majority of the market. While not without risk, the quantitative profile supports a constructive outlook.
KMDA earns a quality score of 80/100, indicating above-average business quality. The company reports a return on equity of 22.3% (sector avg: -2.5%), gross margins of 43.5% (sector avg: 42.5%), net margins of 9.0% (sector avg: -0.2%). Companies in this tier generally demonstrate consistent profitability and efficient capital deployment, though they may face some competitive pressure.
From a valuation perspective, KMDA scores an exceptional 93/100, indicating the stock trades at a deep discount relative to its fundamentals. Key valuation metrics include a P/E ratio of 35.52x, an EV/EBITDA of 3.11x, a P/B ratio of 1.96x. A value score this high suggests the market may be significantly underpricing the company's earnings power, assets, or cash flow generation.
With an investment score of 50/100, KMDA exhibits moderate growth-oriented spending. Key growth metrics include revenue growth of 12.9% vs. a sector average of 5.9% and a return on assets of 15.5% (sector: -0.1%). The company appears to be balancing growth investments with capital returns, though the pace of investment may not be enough to accelerate top-line growth meaningfully.
KMDA demonstrates moderate momentum with a score of 55/100, suggesting a neutral price trend without strong directional conviction. Revenue growth stands at 12.9% year-over-year, while a beta of 0.84 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
KMDA shows good financial stability with a score of 74/100. Key stability metrics include a beta of 0.84 and a debt-to-equity ratio of 4.00x (sector avg: 0.2x). This suggests manageable leverage and moderate price volatility, making it appropriate for investors seeking a balance between growth potential and capital preservation.
KMDA's short interest factor score of 81/100 indicates very low short selling activity relative to peers — a positive signal suggesting institutional investors see limited near-term downside. Specific risk factors include elevated leverage (D/E: 4.00x), small-cap liquidity risk. As a small-cap company with a market capitalization of $350M, KAMADA LTD benefits from the generally lower volatility and deeper liquidity associated with its size class.
KAMADA LTD is a small-cap company in the Manufacturing sector, ranked #48 of 50 in its sector (4th percentile) and #98 of 7,333 overall (99th percentile). Key comparisons include ROE of 22.3% exceeding the -2.5% sector median and operating margins of 12.5% above the 1.3% sector average. This bottom-quartile standing highlights significant competitive headwinds within the Manufacturing space.
Quant Factor Profile
Key factor gap
Value (93) vs Investment (50) — closing this gap could shift the rating.
RANK #48 OF 50 IN INDUSTRIALS
EV/EBITDA 73% BELOW SECTOR MEDIAN (FAVORABLE)
ROE 999% BELOW SECTOR MEDIAN
Gross Margin IN LINE WITH SECTOR BENCHMARKS
AUDIT DATA AS OF DEC 31, 2024 (Q3 FY2024)
We rate KAMADA LTD (KMDA) as a Buy with a composite score of 69.8/100 at a current price of $9.19. The stock scores above average across the majority of our six quantitative factors and ranks #98 out of 7,333 stocks in our universe, reflecting a favorable risk-reward profile.
The rating is primarily driven by strength in value (93th percentile) and quality (80th percentile), which together account for the majority of the composite score. All factors score above the 40th percentile, indicating no material weakness in the quantitative profile. We assign a Narrow Moat rating (56/100), Low uncertainty, and Exemplary capital allocation.
Key items to watch: quarterly earnings execution and sector-level competitive dynamics. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
KAMADA LTD holds a lower-quartile position (#48 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 69.8/100 places it at rank #98 in our full 7,333-stock universe. At $350M in market capitalization, KAMADA LTD is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue is growing at 13%, though momentum at the 55th percentile suggests the market has not yet fully recognized this trajectory. This potential disconnect between fundamental improvement and market recognition could represent an opportunity for patient investors if the growth trend persists.
The margin cascade tells an important story: gross margins of 43% (+1.0pp vs sector) narrow to operating margins of 12% (+11.2pp vs sector) and net margins of 9.0%, yielding a gross-to-net conversion rate of 21%. This conversion rate is typical for the sector, suggesting a standard cost structure without notable efficiency advantages or disadvantages.
At a current price of $9.19, KAMADA LTD appears undervalued relative to its fundamentals. Our value factor score of 93/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The stock screens as attractively priced on a majority of these measures, suggesting the market may be underappreciating the underlying fundamentals.
The stock currently trades at a P/E of 35.5x (a 60% premium to the sector median of 22.3x), EV/EBITDA of 3.1x (discounted to peers), P/B of 2.0x, P/S of 0.8x. The above-sector P/E multiple suggests the market is pricing in superior growth or quality, which our analysis partially supports given strong quality metrics.
The stock's Buy rating (composite score 69.8/100) reflects broad-based quantitative strength, placing it in the top 20% of our 7,333-stock universe.
Gross margins of 43% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
Returns on equity of 22.3% exceed the cost of equity for most companies, indicating genuine shareholder value creation and a reinvestment engine that compounds wealth over time.
Revenue growth of 13% confirms the business is expanding its addressable market — growth at this level typically supports multiple expansion and attracts institutional capital.
A value factor score of 93/100 suggests the market is underpricing these fundamentals, creating a potential margin of safety for new investors.
We assign a Low uncertainty rating to KAMADA LTD. The company exhibits strong financial stability with a beta of 0.84, conservative leverage (4% D/E), and a stability factor in the 74th percentile. The predictable nature of the business model and solid financial position reduce the range of potential outcomes, giving us confidence in our fair value estimate.
We identify no major risk factors at this time. The company's stability factor sits at the 74th percentile with quality at the 80th percentile, both of which support our low-risk assessment. The absence of material leverage, profitability, or volatility concerns reduces the likelihood of a permanent capital loss scenario.
Key risk mitigants include: healthy gross margins of 43% provide a buffer against cost pressures; conservative leverage (4% D/E) limits balance sheet risk; above-average stability (74th percentile) suggests predictable business dynamics. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile is favorable for long-term investors.
We rate KAMADA LTD's capital allocation as Exemplary. Management demonstrates a strong track record of balancing reinvestment with shareholder returns, evidenced by returns on equity of 22.3%, disciplined leverage (4% D/E). Exemplary allocators typically generate returns on equity above 20% while maintaining debt-to-equity below 50% — KAMADA LTD meets this high bar.
The balance sheet remains conservatively managed, providing financial flexibility for opportunistic investments while maintaining a margin of safety for shareholders. We note that the combination of 15.5% return on assets and controlled leverage suggests management is deploying capital at rates well above the cost of capital — the hallmark of exemplary stewardship.
In summary, KAMADA LTD receives a Buy rating with a composite score of 69.8/100 (rank #98 of 7,333). Our quantitative framework assigns a Narrow Moat (56/100, trend: stable), Low uncertainty, and Exemplary capital allocation. The average factor score across quality, value, momentum, stability, and investment is 70/100.
Our analysis supports a constructive view on KAMADA LTD. The combination of identifiable competitive advantages, low uncertainty, and exemplary capital allocation creates a risk-reward profile that favors accumulation at current levels. We recommend investors consider adding this name to portfolios aligned with the stock's risk profile.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We assign KAMADA LTD a Narrow Moat rating with a composite moat score of 56/100. The company possesses identifiable competitive advantages, though they are less entrenched than those of wide-moat peers. Our analysis indicates that KAMADA LTD can sustain above-average returns on invested capital for at least 10 years, with the strongest contributor being margin superiority at 14.8/20.
The strongest moat sources are margin superiority (14.8/20) and growth durability (12.7/20). GM 43% vs sector 43%, OM 12% vs sector 1%. Rev growth 13%, 8yr history. These pillars form the core of KAMADA LTD's competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (7.8/20) and financial resilience (9.8/20). Capital turnover N/A, R&D intensity 9.4%. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect KAMADA LTD's moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 43% providing a solid profitability foundation, operating margins of 12% reflecting effective cost management, moderate revenue growth of 13%. The margin cascade from 43% gross to 12% operating to 9.0% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that the profit engine is high-quality and likely sustainable, with the quality factor at the 80th percentile.
The margin profile shows gross margins of 43%, operating margins of 12%, net margins of 9.0%. Return metrics include ROE of 22.3% and ROA of 15.5%. Relative to the Manufacturing sector, gross margins are 1.0 percentage points above the sector median of 43%, and ROE of 22.3% compares to a sector median of -2.5%.
The balance sheet reflects a conservatively managed balance sheet with D/E of 4%, revenue growth of 13%. The sector median D/E is 0%, putting KAMADA LTD at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
A P/E of 35.5x leaves little room for execution misses — any earnings disappointment could trigger a sharp multiple compression.
Elevated short interest (81th percentile) indicates that sophisticated market participants are betting against the stock.
Above 50MA
37.18%
Net New Highs
+51081
The study, which assessed the pharmacokinetics, safety, tolerability and immunogenicity of AVT80 compared to Entyvio® in healthy adult participants, met all its primary endpoints REYKJAVIK, Iceland, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today positive top-line results from a pharmacokinetic (PK) study for AVT80, a biosimilar candidate to En

Gainers ParaZero Technologies Ltd. (NASDAQ: PRZO) shares jumped 106% to $2.3901 after the company announced an Australian regulator approved first commercial drone flights in populated areas and near people using ParaZero safety systems. HUB Cyber Security Ltd. (NASDAQ: HUBC) shares jumped 60.5% to $0.3836. Phoenix Motor Inc. (NASDAQ: PEV) climbed 48% to $1.48. Phoenix Motor said its EdisonFuture subsidiary launched new Proton Exchange Membrane (PEM) solutions for green hydrogen products and production. Maris-Tech Ltd. (NASDAQ: MTEK) shares climbed 21.1% to $1.2110. Maris-Tech announced its participation in the upcoming Milipol Paris 2023 at the Paris Norde Villepinte exhibition. Senstar Technologies Ltd. (NASDAQ: SNT) surged 20.5% to $1.35. AERWINS Technologies Inc. (NASDAQ: AWIN) gained 19.5% to $0.1688. AERWINS Technologies said its board approved the establishment of a United States subsidiary in Los Angeles, California to pursue the redesign of its XTURISMO Ltd Edition prototype 1 hoverbike. Windtree Therapeutics, Inc. (NASDAQ: WINT) climbed 13.3% to $1.3601. Jin Medical International Ltd. (NASDAQ: ZJYL) rose 16% to $15.93. T2 Biosystems, Inc. (NASDAQ: TTOO) climbed 17% to $0.3075. Vivakor, Inc. (NASDAQ: VIVK) gained 15.6% to $0.96. Singularity Future Technology Ltd. (NASDAQ: SGLY) jumped 15.3% to $0.68. National Western Life Group, Inc. (NASDAQ: NWLI) climbed 13.8% to $474.69 after the company inked a definitive merger deal with Prosperity Life Group for about $1.9 billion in an all-cash transaction. U.S. Energy Corp. (NASDAQ:
Shares of Israeli pharmaceutical giant Teva are down Monday following Hamas's attack over the weekend.
KMDA vs. TECH: Which Stock Is the Better Value Option?